Orgovyx (Relugolix) Patent Expiration, LOE Window & CMS Spending
Orgovyx (Relugolix) by Sumitomo America: FDA Orange Book core substance LOE 2033-09-27 (last listed 2037-09-29), 0 AB generics, $497.0M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Sumitomo America |
| FDA Application & Pathway | N214621 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2033-09-27 |
| Last Listed Patent or Exclusivity Date | 2037-09-29 |
| Orange Book Patents (*PED Extensions) | 12 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $497.0M |
| 2024 Medicare Part D Spend | $484.3M |
| 2024 Medicaid Spend | $12.7M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Sumitomo Pharma America across sibling Meru public-data platforms.